GlassScriptPhysician profile
Bryan H Minton
NPI 1861491995
$1,755.82
in general payments reported to CMS, 2019-2025
27 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $559 · 2021: $113 · 2022: $13.56 · 2023: $200 · 2024: $91.70 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $768.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $292.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $184.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $174.28 | 2019-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $153.94 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $138.18 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Eisai INC. | $103.53 | 2020-2021 | |
| Allergan, INC. | $92.26 | 2019-2020 | |
| Amarin Pharma, INC. | $72.88 | 2019-2020 | |
| Abbott Laboratories | $57.30 | 2023-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.43 | 2020-2025 | Xifaxan |
| Exact Sciences Corporation | $53.74 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $43.55 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.13 | 2021 | |
| Ibsa Pharma INC. | $33.89 | 2023-2025 | Tirosint, Flector, Licart |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $30.01 | 2019-2023 | Veozah |
| Neurocrine Biosciences, INC. | $23.61 | 2025 | |
| Amgen INC. | $22.14 | 2019 | |
| Sanofi Pasteur INC. | $20.08 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $20.07 | 2020 | |
| Daiichi Sankyo INC. | $18.69 | 2020 | |
| Dexcom, INC. | $18.11 | 2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $16.72 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.32 | 2023 | |
| Genentech USA, INC. | $16.25 | 2020 | |
| Dynavax Technologies Corporation | $15.28 | 2020 | |
| Merck Sharp & Dohme LLC | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Minton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.